Sonnet BioTherapeutics Holdings (SONN) said Monday its phase 1 trial of SON-1010 demonstrated a partial response and disease stabilization in adult patients with advanced solid tumors.

One patient in the highest-dose cohort experienced a 45% tumor reduction per RECIST criteria, while 48% of evaluable patients maintained stability at four months, the company said.

No dose-limiting toxicities or related serious adverse events have been reported, with most adverse events being mild and transient, Sonnet said.

Shares of the company surged nearly 116% in recent premarket activity.